EUVIMEDEUVIMED entdecken
Open Access

Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients

Izzet Dogan iD, Anıl Yıldız, Melin Aydan Ahmed, Sezai Vatansever

Indian Journal of Surgical Oncology · 2024-09 · 15 (3) · 489-494

DOI: 10.1007/s13193-024-01936-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Surgical Oncology, online erschienen am 01.04.2024. Verfasst von Izzet Dogan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Istanbul Faculty of Medicine, Istanbul University, Çapa/Fatih, 34093 Istanbul, Turkey. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Different targeted therapy options exist for treating HER2-positive metastatic breast cancer patients. This study evaluated the efficacy and tolerability of the lapatinib plus capecitabine combination after TDM-1 in HER2-positive metastatic breast cancer patients. We retrospectively evaluated the HER2-positive metastatic breast cancer patients' data. The patients who progressed after trastuzumab-based chemotherapy and TDM-1 were included in the study. We used the Kaplan-Meier for survival analysis. Eighteen patients were involved in the study. The average age was 48 (range 31-65). De novo metastatic patient's number was 5 (27.8%). The most common metastatic sites were liver (50%), lung (44.4%), and brain (44.4%), respectively. All patients were previously treated with trastuzumab + chemotherapy and TDM-1. Also, seven (38.9%) patients received hormonotherapy and twelve (66.7%) patients received palliative radiotherapy. The complete response ratio was 5.6%, partial response 11.8%, and stable response 29.4%. Median progression-free survival was found as 5.5 (95% CI, 3.2-7.7) months. The hematological and non-hematological toxicity ratio was 41.2% and 52.9%, respectively. Grade 3-4 toxicity (diarrhea, anemia, and mucositis) was observed in four (22.2%) patients. The median OS duration was 8.2 months (95% CI, 4.3-12.0). Treatment options are limited in heavily pretreated HER2-positive breast cancer patients. Despite a small number of patients, this study showed that the lapatinib plus capecitabine combination was effective and well-tolerated in heavily pretreated HER2-positive breast cancer patients after TDM-1.

Schlagwörter

Stichwörter der Autor:innen

Breast cancerLapatinibMetastasisTDM-1Trastuzumab

Autor:innen und Institutionen

  • Department of Medical Oncology, Istanbul Faculty of Medicine, Istanbul University, Çapa/Fatih, 34093 Istanbul, Turkey.

ORCID-Profile: Izzet Dogan

Zitieren

APA

Dogan, I., Yıldız, A., Ahmed, M. A., & Vatansever, S. (2024). Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients. Indian Journal of Surgical Oncology, 15(3), 489-494. https://doi.org/10.1007/s13193-024-01936-8

Vancouver

Dogan I, Yıldız A, Ahmed MA, Vatansever S. Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients. Indian Journal of Surgical Oncology. 2024;15(3):489-494. doi:10.1007/s13193-024-01936-8

BibTeX
@article{Dogan2024,
  author = {Dogan, Izzet and Yıldız, Anıl and Ahmed, Melin Aydan and Vatansever, Sezai},
  title = {Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients},
  journal = {Indian Journal of Surgical Oncology},
  year = {2024},
  volume = {15},
  number = {3},
  pages = {489--494},
  doi = {10.1007/s13193-024-01936-8}
}
Kostenlos starten →